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heterogeneity should be conducted, and approaches illustrated here can be 
useful to explore heterogeneity. Further evaluation of the value of patient-level 
as opposed to summary-level data in heterogeneity assessment is needed.  
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A COMPARISON OF OUTCOMES IN CLINICAL TRIALS CONDUCTED WITHIN THE 
UNITED STATES VERSUS OUTSIDE THE UNITED STATES  
Stead A1, Rubinstein E2, Jaksa A2, Ho YS2, Daniel K2 
1Context Matters Inc., New York, NY, USA, 2Context Matters, Inc., New York, NY, USA  
OBJECTIVES: The defining characteristics of a disease condition are the same 
across all countries. Therefore, we hypothesize that when assessing a new 
treatment, via a clinical trial, we would expect different countries to value the 
same outcomes irrespective of where the trial was completed. We chose three 
disease conditions that are identified by exact biomarkers to test this hypothesis. 
METHODS: We collected all open, actively enrolling, phase III drug studies from 
www.clinicaltrials.gov for Multiple Sclerosis, Hepatitis C, and HIV. After 
eliminating non-interventional studies and studies with missing information, we 
were left with 39 Multiple Sclerosis, 33 HIV, and 40 Hepatitis C trials. We defined 
three study locations: “U.S. only,” “ex-U.S. only,” and “U.S. and ex-U.S.” Among 
Multiple Sclerosis studies, 13 were U.S.-only, 15 ex-U.S. only, and 11 were U.S. 
and ex-U.S. Among HIV studies, 3 were U.S.-only, 19 ex-U.S. only, and 11 were 
U.S. and ex-U.S. Among Hepatitis C studies none were U.S. only, 23 ex-U.S., and 
17 were U.S. and ex-U.S. Fisher’s exact test was used to examine associations 
between study locations and types of clinical trial outcomes measured. 
RESULTS: We found no statistically significant differences in the outcomes 
evaluated by Multiple Sclerosis studies or HIV studies. Four of the 11 Hepatitis C 
outcome categories evaluated different outcomes depending on location: 
Sustained Virologic Response Week 12 (p-value 0.0011), Laboratory (p-value 
0.0525), AEs (p-value 0.0235), and Safety (p-value 0.0227). CONCLUSIONS: Our 
results support our hypothesis for two of the three conditions we examined, 
Multiple Sclerosis and HIV. However, for Hepatitis C, we found that clinical trials 
outcomes differ by location. The recent surge in development in Hepatitis C 
drugs may explain the discrepancy; however, further research and more data is 
needed.  
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NETWORK META-ANALYSIS OF SURVIVAL DATA. THE VALUE OF 
RECONSTRUCTING DATA FROM PUBLISHED KAPLAN-MEIER CURVES  
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Boston, MA, USA  
OBJECTIVES: Network meta-analysis of published survival data are often based 
on the reported hazard ratio. In this paper we illustrate the value of 
reconstructing data from published Kaplan-Meier curves to perform network 
meta-analysis. METHODS: Published Kaplan-Meier survival curves of trials 
evaluating different interventions for non-small-cell lung cancer were digitally 
scanned. Next, a dataset was created with for each treatment of each trial the 
number of events and number of patients at risk for multiple short time intervals 
over the complete follow-up period. Two types of network meta-analyses were 
performed: 1) For each publication for which no hazard ratio was reported, a 
hazard ratio was estimated based on the scanned curves. Subsequently, all 
hazard ratios of all trials were synthesized with a network meta-analysis model 
assuming a constant hazard ratio (2-step approach); 2) A network meta-analysis 
of the constructed data of the Kaplan-Meier curves of all trials was performed (1-
step approach). RESULTS: The 1-step approach showed that the assumption of a 
constant hazard ratio was not valid for the used dataset. The results of the 1-step 
network meta-analysis could be presented as pooled parametric survival curves. 
CONCLUSIONS: Reconstructing data from published Kaplan-Meier curves allows 
for the inclusion of all relevant studies in a network meta-analysis, even if 
hazard ratios are not reported. Furthermore, it allows for network meta-analysis 
models that do not rely on the assumption of a constant hazard ratio, which 
have great value for cost-effectiveness models.  
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OBJECTIVES: In the last decade, network meta-analysis (mixed treatment 
comparison meta-analysis) has been introduced as a generalization of pair-wise 
meta-analysis. Many randomized controlled trials (RCTs) report treatment effect 
estimates for the outcomes of interest at multiple time points. In this paper we 
compare different methods for network meta-analysis of repeated measures. 
METHODS: Different network meta-analysis models for the synthesis of study 
level data of RCTs evaluating interventions for osteoarthritis were compared: 
separate network meta-analyses per time point; models assuming a linear 
development of treatment effects over time; network meta-analysis models with 
fractional polynomials; and network meta-analysis with splines. All analyses 
were performed in a Bayesian framework. RESULTS: The primary limitation of 
multiple network meta-analyses of study level data by time point was  
the inconsistency in the used evidence base for each time point. Of the models 
that estimate a relationship between outcome and time, fractional polynomials  
had an advantage over splines for the current dataset because the former  
model resulted in more stable parameter estimates and still  
provided sufficient fit to the data. CONCLUSIONS: To understand  
treatment effects over time, reported treatment effects of RCTs need to be 
synthesized simultaneously. Network meta-analysis of longitudinal study level 
data with second order fractional polynomials are a very useful approach to 
evaluate trends of treatment effects over time when there is not too much 
variation in treatment effects from one time point to the next. An additional 
advantage is that the methodology can handle differences in follow-up time 
across trials.  
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OBJECTIVES: 1) To Study the effect of L-carnitine supplementation on behavioral 
symptoms in autistic children; 2) Study the effect of l-Carnitine supplementation 
on Acyl-Carnitine profile of Autistic children; 3) Detect possible correlation 
between the blood Carnitine status and Autistic behavior; and 4) Tolerability 
assessment of l-carnitine supplementation. METHODS: Thirty children 
diagnosed with autism were randomly assigned to receive (100 mg/kg 
bodyweight/day) of liquid l-carnitine (n=16) or placebo (n=14) for 6 months. 
Measurements included changes in childhood autism rating scale (CARS) form 
and free and total carnitine levels using tandem mass spectrometry. RESULTS: 
Results showed significant improvement in CARS scores (P-groups <0.001) and  
(P-overtime= 0.006), with statistically significant differences in free carnitine 
levels (P=0.027) and total carnitine levels (P=0.036 ) . There was no correlation 
between baseline free and total carnitine levels with changes in CARS scores 
from zero to 6 months (r > 0.5 , P> 0.05) and generally L-carnitine therapy was 
well tolerated. In conclusion, L-carnitine therapy (100 mg/kg-bodyweight/day) 
administered for 6 months significantly improved the autism severity, but 
subsequent studies are recommended. CONCLUSIONS: 1) Significant differences 
were found in free and total carnitine levels after therapy; 2) Clinically, L-
carnitine supplementation improves autism severity; 3) L-carnitine therapy was 
well tolerated; and 4) L-carnitine supplements may be given as part of autism 
treatment regimen.  
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OBJECTIVES: Post-authorization interventional clinical trials (CT) and non-
interventional clinical studies (NIS) are increasingly used to evaluate safety and 
other outcomes in real-world settings. Previously, NIS clinical study report (CSR) 
templates used International Society for Pharmacoepidemiology (ISPE; 
www.pharmacoepi.org) reporting guidelines and/or were modified from 
International Conference on Harmonisation (ICH) E3 guidelines. Resulting CSR 
templates may not have contained adequate instructions to develop CSRs for 
regulatory review and subsequent corresponding manuscripts. We reviewed 
various published documents and developed robust NIS CSR templates for use in 
regulatory submission. METHODS: Guidelines reviewed included ISPE (based on 
FDA guidance and EU documents) and Guideline on Good Pharmacovigilance 
Practices – module VIII (www.ema.europa.eu), which describes post-
authorization safety studies (PASS) and updated CSR guidelines, following 
implementation of revised pharmacovigilance legislation in July 2012. For NIS 
manuscripts, STROBE (STrengthening the Reporting of oBservational studies in 
Epidemiology) guidelines (www.strobe-statement.org) were reviewed. We also 
reviewed other NIS-related documents, as well as interventional CT-related 
documents, including ICH CSR guidelines and CONSORT (CONsolidated 
Standards of Reporting Trials) or other design-specific guidelines (www.equator-
network.org) for writing corresponding manuscripts. Additional instructional 
and preferred/optional text was developed for the templates. RESULTS: Overall, 
PASS guidelines provided additional NIS details and were aligned with most 
regulatory sections common in ISPE and aligned closely with STROBE 
statements. ISPE guidelines provided few details for CSR template development. 
Other guidelines and a literature review provided additional CSR template text 
and the inclusion of STROBE–based text supported development of manuscripts. 
By utilizing multiple document sources, new templates were developed that 
contained improved instructions and text while meeting regulatory 
requirements. Furthermore, decision trees were included to support the 
numerous types of NIS study designs. CONCLUSIONS: By aligning CSR guidelines 
with design-specific publication guidelines, template quality was improved for 
regulatory submissions and authors could easily identify important report 
content when writing peer-reviewed publications.  
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OBJECTIVES: To assess the referral patterns and impact for FDG PET/CT for 
treatment management, and to determine the most common metastatic sites in 
breast cancer patients. METHODS: Retrospective analysis was performed on 
2,500 scans reported in Max hospital from November 2009 to March 2012, scans 
for breast cancer patients were separated out (500 scans). Medical records of 122 
consecutive breast cancer patients were retrospectively reviewed. Referral 
categories for PET/CT in breast cancer patients were: Diagnosis, Staging, 
Restaging, Early treatment response evaluation (after 3 cycles of chemotherapy), 
late treatment response evaluation (after 6 cycles of chemotherapy), and 
Radiation therapy response evaluation. RESULTS: PET/CT was mostly used for 
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early treatment response evaluation in 82 (67.21%) of the patients, for staging in 
65 (53.28%) patients, late treatment responseevaluation in 48 (39.34%) patients, 
for restaging in 40 (32.79%) patients. PET/CT was not used for diagnosis and 
radiation treatment response evaluation. Major histologic subtype was found to 
be infiltrating ductal carcinoma (IDC) (91%). liver was the most common 
metastatic site among all (41 patients) 85.37% in 35 patients, lung in 30 patients 
(73.17%), bone in 25 patients (60.98%), around 3 patients were having lesions in 
brain, adrenal and ovaries, around (4.88%) 2 patients were presented with lesion 
in atrium. Recurrence was present in 31(76%) patients, chest wall invasion in 10 
patients (24%). Maximum number of patients around 21 patients had lesions in 
ipsilateral axillary nodes (51.22%), 16 in supraclavicular nodes (39.02%) and 13 
patients (31.71%) in contralateral nodes. Treatment plan was altered in 55 
patients (45.08%), whereas supported in 67 patients (54.92%). CONCLUSIONS: The 
clinical utility of PET/CT may lead to a change in the routine diagnostic 
algorithm and follow-up protocols for patients with cancer by providing correct 
and early diagnosis of recurrence as well as by establishing its precise 
significance for further clinical management.  
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AN EVALUATION OF MEDICATION ERRORS IN A LARGE TEACHING  
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OBJECTIVES: A lot of studies regarding medication errors are reported and 
published worldwide. We also face a big challenge of medication errors in our 
country. This study aims to explore the types of medication errors in drug 
administration in a large teaching hospital which is a reflection of the 
medication errors in the whole country. METHODS: Trainee Pharmacists from 3 
different batches of Pharmacy in my supervision were assigned to examine the 
errors in different clinical units of the hospital. The study was based on their 
personal monitoring and patients’ interviews regarding the medication 
administration. The results were collected from 1900 patients and the study 
period was from June, 2008 to November, 2010. RESULTS: We had detected 910 
medication errors out of 1900 patients only in drug administration. In each 
category the medication errors were omission: 387(42.5%), time: 291(32%), 
unauthorized drug: 89(9.8%), wrong rate: 70(7.7%), wrong route: 56(6%) and wrong 
dosage form: 17(2%). The health care professionals involved in these medication 
errors were nurses and the reason was lack of hospital Pharmacists in each 
nursing unit. CONCLUSIONS: Different areas in our country and other 
developing countries might have these problems/results. There is a dire need for 
the induction of hospital Pharmacists in the health care system to overcome 
these types of medication errors which leads to about 40% accidents and 
incidents in drug administration. Nurses involved in these medication errors 
should be trained for proper use and administration of the drugs to the in-
patients in particular. This study also indicates that this type of practice is the 
reflection of state and regulatory affairs in the country and this is a warning for 
all developing countries.  
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DEVELOPMENT OF AN ALGORITHM THAT DIFFERENTIATES AMONG RISK 
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OBJECTIVES: A common limitation of the peer-reviewed literature is failure to 
establish whether a condition precedes or follows disease diagnosis. If disease 
diagnosis comes first, the condition is either a comorbidity or consequence of 
the disease, whereas if the condition precedes disease diagnosis, it may be a risk 
factor. Our objective was to develop an algorithm for appropriate classification of 
risk factors, comorbidities, and consequences of disease to enable accurate 
assessment of the literature. METHODS: We established the following procedure 
to identify risk factors in articles retrieved through our literature search: 1) 
exclude cross-sectional studies as potential sources of risk factor data because 
they cannot establish the necessary temporal sequence; 2) if the terms ‘risk 
factor’ or ‘incidence’ are present in the remaining articles, include only those 
that: a) report on a population followed over time; b) contain baseline data 
indicating absence of signs/symptoms of the disease of interest at study onset; 
and c) have conducted statistical analyses demonstrating associations between 
individual baseline factors and the disease. If these requisites are not met, 
signs/symptoms present at study onset should be classified as comorbid 
conditions. Conditions arising as a result of the condition may be classified as 
disease consequences. RESULTS: We systematically applied our algorithm to 100 
peer-reviewed articles in clinically focused journals retained for inclusion after 
screening. The algorithm allowed for accurate classification of risk factors (ie, 
underlying conditions that predispose a patient to development of the disease), 
comorbidities (ie, conditions that complicate disease progress), and 
consequences of the disease (ie, events shown to be statistically related to the 
disease and occurring after disease onset). CONCLUSIONS: We have developed 
an algorithm that accurately differentiates among risk factors, comorbidities, 
and consequences of a disease. This tool will aid in the accurate assessment of 
clinical literature when conducting systematic reviews.  
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OBJECTIVES: In the biopharmaceutical industry, site-based studies are the norm 
for evaluating drug safety and efficacy. Recently patient-centered studies (PCSs) 
have gained popularity. These studies offer advantages over site-based studies, 
but present unique challenges. This abstract seeks to describe the patient-
centered approach and associated challenges and opportunities. METHODS: This 
descriptive study reviews operational and design issues of PCSs and discusses 
utility, advantages, and challenges. RESULTS: PCSs revolve around patients. 
They use an open-enrollment model whereby all eligible patients can self-enroll 
directly, thereby maximizing enrollment. Enrollment is not limited to patients 
treated at particular study sites. These studies typically employ a single site and 
“virtual” study coordinating center to screen/enroll patients and collect data, 
thus reducing site costs. PCSs are used extensively for pregnancy registries and 
other rare-exposure/disease registries, and more recently for clinical trials. This 
unique approach requires buy-in from regulatory agencies and IRBs. Recruitment 
activities should cast a wide net using various means targeted to the population 
(e.g., internet and social media recruitment sources for younger patients; 
television, radio, or print media for older patients). Streamlined patient 
screening, informed consent (e.g., on-line consent or waivers of written consent), 
and data collection processes are essential. Retention is facilitated by engaging 
participants in the reporting process, minimizing reporter burden, and providing 
ongoing support using various means targeted to the population (e.g., internet or 
mobile apps for younger patients and human support through coordinating 
centers for older patients). It may also be critical to obtain medical release to 
verify patient-reported medical data from treating physicians. However, 
discrepancies between patient-reported and physician-reported data may pose 
challenges in analyses and reporting. CONCLUSIONS: PCSs offer advantages 
such as maximizing enrollment and reducing site costs, but pose regulatory, 
operational, and analytic challenges. Researchers opting to employ PCSs must 
weigh challenges versus opportunities in the design phase.  
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STUDYING DRUG SAFETY IN PREGNANCY: DIFFERENT APPROACHES, SAME 
CONCLUSIONS?  
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OBJECTIVES: Various methods are used to monitor safety of drug exposures in 
pregnancy, including prospective pregnancy registries, longitudinal database 
studies, and case-control studies. This abstract seeks to evaluate these approaches 
and examine impact on interpretation of results. METHODS: Study designs for the 
three types of pregnancy monitoring studies were examined to determine strengths 
and limitations in effectively monitoring drug safety in pregnancy and the types of 
conclusions that can meaningfully be drawn from each. RESULTS: Pregnancy 
registries are prospective studies with active data collection from reliable sources 
providing detailed, quality data on exposure and outcome. Their voluntary nature 
can lead to selection bias and a lengthy enrollment period may be needed to reach 
sufficient sample size/power. Longitudinal database studies are population based 
and offer timely and cost-efficient results, but often require complex linkage of 
multiple databases. Misclassification bias can occur because critical variables 
(exposure and outcome) may lack precision/detail. Case-control studies begin with 
the outcome of interest and retrospectively assess drug exposure offering 
substantial statistical power to identify teratogens among relatively rare exposures, 
but are subject to recall bias. Only registries are useful in monitoring safety early in 
the drug lifecycle. Pregnancy registries can detect major teratogenic effects, but 
have limited power to detect risk of specific birth defects. Database studies can 
detect major teratogenic effects and due to their large size/power may also detect 
risk of specific defects. Both approaches can assess other outcomes. Case-control 
studies provide insights into the strength of association between exposure and a 
specific defect, but cannot be used to estimate birth defect prevalence or other 
outcomes. CONCLUSIONS: All three approaches are viable for studying drug safety 
in pregnancy, but differ in the types of conclusions that may be drawn. In choosing 
a design, it is important to consider study objectives and outcomes of interest.  
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MEDICAID POPULATION  
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OBJECTIVES: Naturally occurring catastrophic events not only disrupt economic 
activity but also impact access to essential health services. The purpose of this 
study is to quantify the long-term impact of Hurricane Katrina on continuously-
eligible epilepsy patients’ health care utilization pre-and post-Hurricane Katrina 
(August 29, 2004-August 28, 2007). METHODS: This study was a population-based 
retrospective analysis of the Louisiana Medicaid database. Frequency counts of 
demographic variables age, gender, race and region were computed. Segmented 
regression analysis was applied to the longitudinal data to analyze changes in 
emergency room (ER) utilization, the number of patients receiving anti-epileptic 
medication, the total number of prescriptions utilized and the average cost of 
pharmacy claims. In effect, the dependent variables were regressed against 1) 
total time (months); 2) Katrina as a discrete event; and 3) time post-Katrina 
(months). RESULTS: A total of 1371 epileptic patients in the Louisiana Medicaid 
population was found of which 2/3rds were 18-64 years of age, 49% African-
American and 53.1% were males. Patients were primarily from Baton Rouge 
(44%), New Orleans (36%) and Acadiana (21%). Results of segmented regression 
analysis revealed that ER utilization was significantly related to all three time 
variables. Katrina as a discrete event was statistically significant in relation to 
the number of epileptic patients receiving prescriptions and the number of 
prescriptions utilized, whereas the average cost per prescription claim was 
